Basis of Presentation and Summary of Significant Accounting Policies (Tables)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Sep. 30, 2022

The related first quarter of fiscal 2023 restructuring charges were recorded in the income statement as follows (in thousands):



	Employee		Asset
	severance		related and other		Total
Selling, general and administrative	$	1,328	$	842	$	2,170

Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):


	Employee		Asset
	severance		related and other		Total
Expense incurred in the first quarter of 2023	$	1,328	$	842	$	2,170
Cash payments		(420)		(431)		(851)
Adjustments		—		(72)		(72)
Accrued restructuring actions balances as of September 30, 2022	$	908		339		1,247

Diagnostics and Genomics [Member]

Notes Tables

Schedule of restructuring charges

Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands):

:
	Employee		Asset
	severance		Impairment and other		Total
Selling, general and administrative	$	649	$	750	$	1,399


	Employee		Asset
	severance		Impairment and other		Total
Expense incurred in the first quarter of 2022	$	639	$	546	$	1,185
Incremental expense incurred during fiscal 2022		—		242		242
Cash payments		(589)		(554)		(1,143)
Adjustments⁽¹⁾		(50)		(234)		(284)
Accrued restructuring actions balances as of June 30, 2022	$	—		—		—

⁽¹⁾Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange.

Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)